Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis
BackgroundSerum sphingolipids are widely involved in the development of hepatocellular carcinoma (HCC). We investigated the serum sphingolipid profile in patients with HCC or cirrhosis and explored the potential diagnostic efficiency of serum sphingolipid metabolites which may be helpful in differen...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.01759/full |
| _version_ | 1828961617364123648 |
|---|---|
| author | Yingying Jiang Yingying Jiang Cai Tie Yang Wang Yang Wang Dandan Bian Dandan Bian Mei Liu Mei Liu Ting Wang Ting Wang Yan Ren Yan Ren Shuang Liu Shuang Liu Li Bai Li Bai Yu Chen Yu Chen Zhongping Duan Zhongping Duan Sujun Zheng Sujun Zheng Jinlan Zhang |
| author_facet | Yingying Jiang Yingying Jiang Cai Tie Yang Wang Yang Wang Dandan Bian Dandan Bian Mei Liu Mei Liu Ting Wang Ting Wang Yan Ren Yan Ren Shuang Liu Shuang Liu Li Bai Li Bai Yu Chen Yu Chen Zhongping Duan Zhongping Duan Sujun Zheng Sujun Zheng Jinlan Zhang |
| author_sort | Yingying Jiang |
| collection | DOAJ |
| description | BackgroundSerum sphingolipids are widely involved in the development of hepatocellular carcinoma (HCC). We investigated the serum sphingolipid profile in patients with HCC or cirrhosis and explored the potential diagnostic efficiency of serum sphingolipid metabolites which may be helpful in differentiating HCC including α-fetoprotein (AFP)-negative HCC from cirrhosis.MethodsSeventy-two HCC patients (including 24 AFP-negative HCC) and 104 cirrhotic patients were consecutively enrolled in this study. High-performance liquid chromatography–tandem mass spectrometry was used to detect a panel of 57 serum sphingolipid metabolites.ResultsTwenty-four sphingolipid metabolites showed significant differences between HCC and cirrhotic patients (all P < 0.05). Sphingosine (d18:1)-1-P was found to have the potential to differentiate HCC from cirrhosis by orthogonal partial least squares discriminant analysis (OPLS-DA). There was no significant difference in the efficacy of Sphingosine (d18:1)-1-P and AFP to distinguish HCC from cirrhosis, and the area under the receiver operating curve (AUC) were 0.85 and 0.83 (P > 0.05), respectively. When the cut-off value of Sphingosine (d18:1)-1-P was set at 56.29 pmol/0.1 ml, the sensitivity and specificity were 79.20% and 78.70%, respectively. Notably, the upregulation of Sphingosine (d18:1)-1-P could also distinguish AFP-negative HCC from cirrhosis with an AUC of 0.79. The sensitivity and specificity were 62.50% and 77.90% at a cut-off value of 56.29 pmol/0.1 ml. Spearman rank correlation analysis revealed that serum Sphingosine (d18:1)-1-P was not correlated with AFP in patients with cirrhosis, AFP-positive HCC, and AFP-negative HCC. Moreover, the difference in the diagnostic efficiency of serum Sphingosine (d18:1)-1-P was not statistically significant between tumor size (≤2 cm vs. >2 cm, P = 0.476). Also, there was no difference among patients with different TNM stages and BCLC stages.ConclusionThe upregulation of serum Sphingosine (d18:1)-1-P exhibits good diagnostic performance for HCC. Particularly, Sphingosine (d18:1)-1-P could also serve as a biomarker for the diagnosis of AFP-negative HCC. These findings may contribute to the non-invasive diagnosis of HCC including AFP-negative HCC. |
| first_indexed | 2024-12-14T09:48:36Z |
| format | Article |
| id | doaj.art-e5249afd1c4d4f118825287195c7546c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-14T09:48:36Z |
| publishDate | 2020-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e5249afd1c4d4f118825287195c7546c2022-12-21T23:07:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-09-011010.3389/fonc.2020.01759538088Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From CirrhosisYingying Jiang0Yingying Jiang1Cai Tie2Yang Wang3Yang Wang4Dandan Bian5Dandan Bian6Mei Liu7Mei Liu8Ting Wang9Ting Wang10Yan Ren11Yan Ren12Shuang Liu13Shuang Liu14Li Bai15Li Bai16Yu Chen17Yu Chen18Zhongping Duan19Zhongping Duan20Sujun Zheng21Sujun Zheng22Jinlan Zhang23Difficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaInstitute of Materia Medica, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, ChinaDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaInstitute of Materia Medica, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, ChinaBackgroundSerum sphingolipids are widely involved in the development of hepatocellular carcinoma (HCC). We investigated the serum sphingolipid profile in patients with HCC or cirrhosis and explored the potential diagnostic efficiency of serum sphingolipid metabolites which may be helpful in differentiating HCC including α-fetoprotein (AFP)-negative HCC from cirrhosis.MethodsSeventy-two HCC patients (including 24 AFP-negative HCC) and 104 cirrhotic patients were consecutively enrolled in this study. High-performance liquid chromatography–tandem mass spectrometry was used to detect a panel of 57 serum sphingolipid metabolites.ResultsTwenty-four sphingolipid metabolites showed significant differences between HCC and cirrhotic patients (all P < 0.05). Sphingosine (d18:1)-1-P was found to have the potential to differentiate HCC from cirrhosis by orthogonal partial least squares discriminant analysis (OPLS-DA). There was no significant difference in the efficacy of Sphingosine (d18:1)-1-P and AFP to distinguish HCC from cirrhosis, and the area under the receiver operating curve (AUC) were 0.85 and 0.83 (P > 0.05), respectively. When the cut-off value of Sphingosine (d18:1)-1-P was set at 56.29 pmol/0.1 ml, the sensitivity and specificity were 79.20% and 78.70%, respectively. Notably, the upregulation of Sphingosine (d18:1)-1-P could also distinguish AFP-negative HCC from cirrhosis with an AUC of 0.79. The sensitivity and specificity were 62.50% and 77.90% at a cut-off value of 56.29 pmol/0.1 ml. Spearman rank correlation analysis revealed that serum Sphingosine (d18:1)-1-P was not correlated with AFP in patients with cirrhosis, AFP-positive HCC, and AFP-negative HCC. Moreover, the difference in the diagnostic efficiency of serum Sphingosine (d18:1)-1-P was not statistically significant between tumor size (≤2 cm vs. >2 cm, P = 0.476). Also, there was no difference among patients with different TNM stages and BCLC stages.ConclusionThe upregulation of serum Sphingosine (d18:1)-1-P exhibits good diagnostic performance for HCC. Particularly, Sphingosine (d18:1)-1-P could also serve as a biomarker for the diagnosis of AFP-negative HCC. These findings may contribute to the non-invasive diagnosis of HCC including AFP-negative HCC.https://www.frontiersin.org/article/10.3389/fonc.2020.01759/fullhepatocellular carcinomacirrhosisAFPsphingolipidserum |
| spellingShingle | Yingying Jiang Yingying Jiang Cai Tie Yang Wang Yang Wang Dandan Bian Dandan Bian Mei Liu Mei Liu Ting Wang Ting Wang Yan Ren Yan Ren Shuang Liu Shuang Liu Li Bai Li Bai Yu Chen Yu Chen Zhongping Duan Zhongping Duan Sujun Zheng Sujun Zheng Jinlan Zhang Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis Frontiers in Oncology hepatocellular carcinoma cirrhosis AFP sphingolipid serum |
| title | Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis |
| title_full | Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis |
| title_fullStr | Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis |
| title_full_unstemmed | Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis |
| title_short | Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis |
| title_sort | upregulation of serum sphingosine d18 1 1 p potentially contributes to distinguish hcc including afp negative hcc from cirrhosis |
| topic | hepatocellular carcinoma cirrhosis AFP sphingolipid serum |
| url | https://www.frontiersin.org/article/10.3389/fonc.2020.01759/full |
| work_keys_str_mv | AT yingyingjiang upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT yingyingjiang upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT caitie upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT yangwang upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT yangwang upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT dandanbian upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT dandanbian upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT meiliu upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT meiliu upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT tingwang upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT tingwang upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT yanren upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT yanren upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT shuangliu upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT shuangliu upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT libai upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT libai upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT yuchen upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT yuchen upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT zhongpingduan upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT zhongpingduan upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT sujunzheng upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT sujunzheng upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis AT jinlanzhang upregulationofserumsphingosined1811ppotentiallycontributestodistinguishhccincludingafpnegativehccfromcirrhosis |